Objective To observe the effect of ulinastatin on NT -proB -NP and Picco in patients with severe sepsis.Methods 50 patients with severe sepsis were randomly divided into the control group and observation group,25 patients in each group.The control group received the routine treatment,and the observation group received ulinastatin additionally.The venous blood was collected to determine cTn -I,NT -proBNP,TNF -αand Lac before treatment and 7 days after treatment.The APACHE Ⅱ and CFI were observed before treatment and 7 days after treat-ment.Results The differences of CFI,cTnI,NT -proBNP in the two groups before treatment were not significant (t =0.419,0.321,0.335,all P >0.05),after treatment,cTnI and NT -proBNP decreased more significantly(t =2.976,2.910,all P <0.05),while lifting more apparent CFI[(3.98 ±0.95)vs.(2.39 ±0.85),t =6.237,P <0.05]in the observation group than in the control group.The differences of TNF -αand Lac in the two groups before treatment were not significant (t =0.602,0.848,all P >0.05 ),after treatment,TNF -αand Lac decreased significantly faster in the observation group than in the control group(t =8.478,3.104,all P <0.05).After treat-ment,APACHE Ⅱ score decreased significantly in observation group than in the control group(t =2.321,P <0.05). Conclusion Ulinastatin had protective effects on heart function in patients with severe sepsis.

By means of the observation of acridine orange-stained lysosomes with fluorescence microscope, we studied the intracellular killing and digestive process after alveolar macrophage (AM) ingested living-yeast. Based on the morphological changes of the cells, we divided the process into three stages: the pre-phagosome-lysosome fusion stage, the phagosome-lysosome fusion and killing stage, and the digestive stage. The results revealed that all the values of phagocytic index, phagocytic rate, fusion index and fusion rate of the isolated AM of rabbits infected with living-BCG were higher than those of normal rabbits (P

Alveolar macrophages (AM) were studied by means of phase contrast microscope, differential interference contrast microscope, SEM and TEM. The content of AcP, LDH, SDH of the AM was measured by MPV3-TSA microspectrophotometerimage analytical instrument. Under phase contrast microscope, two different types of AM can be distinguished, i. e, the light cells and the dark cells. The two types of cells are spherical and flat in shape under differential interference contrast microscope. The observation with SEM and TEM showed that the spherical cells possess more filopodia and more lysosomes in cytoplasm, but the flat cells possess more lamellar podia. Quantitative cytochemistry demonstrated that the content of AcP, LDH, SDH in spherical cells are much more than that of flat cells. The results suggest that there are two types of alveolar macrophages exist in normal rat lung.

The phagocytic ability and fashion of two types of alveolar macrophages (AM) on coal dust were studied by differential interference contrast microscope, scanning electron microscope and image analyser. This study revealed the phagocytic ability of spherical AM on dust was higher than that of the flat AM. Both types of AM could extend long tenuous filopodia to the coal dusts around the cells. The coal dusts were attached to the cell surface and then were sunk into the macrophage. The amount of the phagocyted coal dusts per unit time were measured by image analytical method which is more exact than other methods. This paper provided not only a new approach for study phagocytosis of macrophage on inorganic dusts, but also some essential morphologic evidences for study of pneumoconiosis.

Objective To investigate the changes and the significance of the contents in matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in plasm of patients with intracerebral hemorrhage (ICH). Methods The contents of MMP-2 and MMP-9 in plasm of 50 patients with ICH and 50 healthy people (control group) were measured respectively through ELISA methods. Results Compared with the control group,the increase of the contents of MMP-2 and MMP-9 had obvious statistic significance in plasm of patients with ICH (P0.05),but they had obvious statistic significance in the comparison among other time groups (P

BACKGROUND: Transplantation of the human umbilical cord blood mononuclear cells (HUCBCs) have received increasing attention, as a promising candidate for the cellular transplantation, but the majority of the existing studies are basic research.OBJECTIVE: To report a patient of extensive anterior-wall acute myocardial infarction with cardiogenic shock and severe heart failure, after treatment of HUCBCs transplantation. METHODS: A 73-year-old female patient with cardiogenic shock and severe heart failure after extensive anterior-wall acute myocardial infarction was treated with percutaneous coronary intervention (three scaffolds implantation) and medications, and she still appeared the symptoms of congestive heart failure, such as severe recurrent dyspnea. 2.4 × 108 HUCBCs (50 mL cell suspension) was injected into the infarcted myocardium through the left anterior descending artery by using coronary micro-guide catheter.RESULTS AND CONCLUSION: The patient reported profound clinical benefit including improvement of heart-failure-associated symptoms after the transplantation. Notably the patient did not experience the cell transplant-related side effects during 4 months of follow-up. The ejection fraction increased from 22% before the transplantation to 53% at 21 days after the transplantation. The B-type natriuretic peptide decreased from 1 730 ng/L before the transplantation, 854 ng/L after the transplantation to 264 ng/L at 21 days after the transplantation. The patient did not appear the symptoms of congestive heart failure, including dyspnea, chest distress and hypodynamia, she returned to daily activity at 4 months of follow-ups. Experimental findings indicate that the HUCBCs transplantation is an effective and safe means for patients cardiogenic shock and severe heart failure after acute myocardial infarction.

BACKGROUND:Myocardial infarction patients commonly appear to have left ventricular remodeling and heart failure. Because of physical characteristics, these two complications are more likely to occur in elderly patients with myocardial infarction. In recent years, stem celltransplantation in the treatment of acute myocardial infarction and heart failure has become a hot topic, and the feasibility and safety has been confirmed, but its long-term outcomes in elderly patients are stil unclear.
OBJECTIVE:To assess the long-term effect of transplantation of autologous peripheral blood stem cells on the left ventricular remodeling and heart function in the old patients with myocardial infarction.
METHODS:Thirty old patients (age ≥ 60 years) with myocardial infarction were randomly assigned to receive intracoronary transplantation of peripheral blood stem cells fol owing bone marrow cells mobilization by granulocyte colony-stimulating factor ( 300-600μg per day) subcutaneously for 5 days in addition to conventional therapy (standard drug therapy and percutaneous coronary intervention;transplantation group, n=15) or standard therapy (standard drug therapy and percutaneous coronary intervention;control group, n=15) . Complications during intervention, left ventricular function and left ventricular remodeling at baseline and 6, 12, 24, 60 months after treatment were monitored.
RESULTS AND CONCLUSION:Left ventricular function, left ventricular end diastolic volume, and left ventricular end-systolic volume were significantly improved 6,12, 24, 60 months after autologous peripheral blood stem celltransplantation compared to baseline, while these parameters remained unchanged in the control group. These parameters had statistical difference between the two groups after treatment. During the fol ow-up, no severe side effects were observed. These findings indicate that autologous peripheral blood stem celltransplantation leads to significant and longstanding improvements in left ventricular performance of old patients with myocardial infarction, and shows good safety.

Objective This study was designed to evaluate the short-term effect and safety of 80 mg/d atorvastatin treating on ACS patients with interventional therapy in China. Methods From August 2002 to March 2014,1746 ACS patients accepting 80mg/d atorvastatin treatment were enrolled from three province hospital. All patients were divided into three groups, 886 patients in group A with 80mg/d atorvastatin treating for 4 weeks, 562 patients in group B with 80mg/d atorvastatin treating for 8 weeks, and 298 patients in group C with 80mg/d atorvastatin treating for 12 weeks after discharge. Blood lipid level, hepatic function, renal function and creatine kinase level were tested on 4th, 8th, 12th week. Results The percentage of patients reacting lipid levels was 85.0%in group A, 86.1%in group B, 94.0%in group C and 86.9%in total. The rate of ALT/AST exceed two times of normal upper level in group A was 1.6%, in group B was 1.8%and in group C was 1.0%.The symptom of joint and muscle pain in group A was 6.3%, group B was 1.4%, group C was 2.7%. The elevation of creatine kinase in group A was 0.8%, in group B was 0.5%, and 0%in group C. The symptom of abdomen discomfort in group A was 2.3%, group B was 2.5%and group C was 4.0%. The complaint of other symptoms was 3.2%in group A, 2.1%in group B, 1.7%in group C. Conclusions Accepting 80 mg/d atorvastatin treating for ACS patients with interventional therapy is effective and safe in short term.

Thyroid cancer is the most common malignant tumor of the human endocrine system. A papillary thyroid microcarci-noma (PTMC) is usually defined as a papillary thyroid tumor that is less than 10 mm in diameter. The incidence of thyroid cancers has obviously increased in recent years. The surgical treatment of PTMC differs in China and overseas. Aside from conventional surgery, novel surgical methods, such as ultrasound-guided percutaneous ablation, have been used for the surgical treatment of PTMC. This arti-cle mainly discusses the research progress in the surgical treatment of PTMC.

Hepatic Encephalopathy ; classification ; diagnosis ; therapy ; Humans ; Terminology as Topic